WIP (Y455) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
WIP (Y455) Peptide Applications :
Blocking Background :
Mutations in the Wiskott-Aldrich syndrome protein (WASP) often result in immunodeficiency due to abnormal T cell and B cell activation. The 503 amino acid WAS-interacting protein (WIP) contains a number of domains implicated in Actin-binding and several putative SRC homology-binding domains. The first 100 amino acids of WASP interact with amino acids 377-503 of WIP, and the majority of pathogenic mutations associated with WAS occur within the first 100 amino acids of WASP. The gene encoding human WIP maps to chromosome 2q31.1. Overexpression of WIP in the human B cell line BJAB increases F-Actin content and cerebriform projections. While both WIP and Vav cooperate in the regulation of NF-AT/AP-1 gene transcription, the WIP-WASP complex is required for activation of NF-AT/AP-1 necessary for proper T cell function. A dysfunctional WIP-WASP complex may be implicated in the immunodeficient phenotype in WAS. Alternative Name :
AI115543; D2Ertd120e; MGC111041; Protein PRPL-2; PRPL 2; PRPL-2 protein; WAS/WASL interacting protein family member 1; WAS/WASL-interacting protein family member 1; WASP-interacting protein; WASPIP; WIP; Wipf1; WIPF1; Wiskott-Aldrich syndrome protein interacting protein; Wiskott-Aldrich syndrome protein-interacting protein; Swiss-Prot :
O43516 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide WIP (Y455). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS9169 WIP (Y455) pAb.
WIP (Y455) Peptide Applications :
Blocking Background :
Mutations in the Wiskott-Aldrich syndrome protein (WASP) often result in immunodeficiency due to abnormal T cell and B cell activation. The 503 amino acid WAS-interacting protein (WIP) contains a number of domains implicated in Actin-binding and several putative SRC homology-binding domains. The first 100 amino acids of WASP interact with amino acids 377-503 of WIP, and the majority of pathogenic mutations associated with WAS occur within the first 100 amino acids of WASP. The gene encoding human WIP maps to chromosome 2q31.1. Overexpression of WIP in the human B cell line BJAB increases F-Actin content and cerebriform projections. While both WIP and Vav cooperate in the regulation of NF-AT/AP-1 gene transcription, the WIP-WASP complex is required for activation of NF-AT/AP-1 necessary for proper T cell function. A dysfunctional WIP-WASP complex may be implicated in the immunodeficient phenotype in WAS. Alternative Name :
AI115543; D2Ertd120e; MGC111041; Protein PRPL-2; PRPL 2; PRPL-2 protein; WAS/WASL interacting protein family member 1; WAS/WASL-interacting protein family member 1; WASP-interacting protein; WASPIP; WIP; Wipf1; WIPF1; Wiskott-Aldrich syndrome protein interacting protein; Wiskott-Aldrich syndrome protein-interacting protein; Swiss-Prot :
O43516 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide WIP (Y455). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS9169 WIP (Y455) pAb.
Blocking peptide available as BS9169PP